Trial Profile
Phase III trial of XP 23829 in patients with relapsing multiple sclerosis
Status:
Planning
Phase of Trial:
Phase III
Latest Information Update: 17 Jan 2014
Price :
$35
*
At a glance
- Drugs Tepilamide-fumarate (Primary)
- Indications Multiple sclerosis
- Focus Registrational; Therapeutic Use
- Sponsors XenoPort
- 17 Jan 2014 New trial record